Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis

BACKGROUND: Dovitinib is a receptor tyrosine kinase (RTK) inhibitor targeting vascular endothelial growth factor receptors, fibroblast growth factor receptors and platelet-derived growth factor receptor β. Dovitinib is currently in clinical trials for the treatment of hepatocellular carcinoma (HCC)....

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Chen, Zhi-Yuan, Shi, Ming, Peng, Li-Xia, Wei, Wei, Li, Xin-Jian, Guo, Zhi-Xing, Li, Shu-Hong, Zhong, Chong, Qian, Chao-Nan, Guo, Rong-Ping
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2012
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3552726/
https://ncbi.nlm.nih.gov/pubmed/23228017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-10-245
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars